Ado-trastuzumab emtansine and radium 223 dichloride

Dominic Solimando, James Waddell

Research output: Contribution to journalArticle

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804,e-mail: waddfour@charter.net.

Original languageEnglish (US)
Pages (from-to)729-733
Number of pages5
JournalHospital Pharmacy
Volume48
Issue number9
DOIs
StatePublished - Nov 4 2013

Fingerprint

Radium
Oncology
Pharmacists
Pharmaceutical Services
Chemotherapy
Poisons
Highway systems
Postal Service
Antineoplastic Agents
Drug Therapy
Neoplasms
ado-trastuzumab emtansine
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Ado-trastuzumab emtansine and radium 223 dichloride. / Solimando, Dominic; Waddell, James.

In: Hospital Pharmacy, Vol. 48, No. 9, 04.11.2013, p. 729-733.

Research output: Contribution to journalArticle

Solimando, Dominic ; Waddell, James. / Ado-trastuzumab emtansine and radium 223 dichloride. In: Hospital Pharmacy. 2013 ; Vol. 48, No. 9. pp. 729-733.
@article{88be5d193dd4409ba0ed627b06d20b54,
title = "Ado-trastuzumab emtansine and radium 223 dichloride",
abstract = "The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804,e-mail: waddfour@charter.net.",
author = "Dominic Solimando and James Waddell",
year = "2013",
month = "11",
day = "4",
doi = "10.1310/hpj4809-729",
language = "English (US)",
volume = "48",
pages = "729--733",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "9",

}

TY - JOUR

T1 - Ado-trastuzumab emtansine and radium 223 dichloride

AU - Solimando, Dominic

AU - Waddell, James

PY - 2013/11/4

Y1 - 2013/11/4

N2 - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804,e-mail: waddfour@charter.net.

AB - The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr., President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804,e-mail: waddfour@charter.net.

UR - http://www.scopus.com/inward/record.url?scp=84886683250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886683250&partnerID=8YFLogxK

U2 - 10.1310/hpj4809-729

DO - 10.1310/hpj4809-729

M3 - Article

VL - 48

SP - 729

EP - 733

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 9

ER -